Cassell G H, Davis J K
Infect Immun. 1978 Jul;21(1):69-75. doi: 10.1128/iai.21.1.69-75.1978.
Intravenous vaccination of rats with either viable or Formalin-inactivated Mycoplasma pulmonis reduced the incidence and severity of lower respiratory tract lesions after intranasal challenge with viable organisms. Intranasal vaccination with killed organisms reduced the severity of rhinitis, but did not affect lesions in any other region of the respiratory tract. The maximum protection against upper tract lesions (rhinitis, otitis, and laryngotracheitis) was provided by intravenous immunization with viable organisms. Dual vaccination (intraperitoneal plus intranasal) with killed organisms provided no significant protection in any segment of the tract. However, these ineffective vaccine regimens did not potentiate the lesions. These results conclusively demonstrate that vaccination of rats against mycoplasma respiratory disease is feasible and also suggest that systemic vaccination may provide greater protection for the lungs than intranasal vaccination, at least when equivalent antigen doses are used.
用活的或福尔马林灭活的肺支原体对大鼠进行静脉接种，可降低经鼻接种活病原体后下呼吸道病变的发生率和严重程度。用灭活病原体进行鼻内接种可降低鼻炎的严重程度，但不影响呼吸道其他区域的病变。静脉接种活病原体可提供对上呼吸道病变（鼻炎、中耳炎和喉气管炎）的最大保护。用灭活病原体进行双重接种（腹腔内加鼻内）在呼吸道的任何部位均未提供显著保护。然而，这些无效的疫苗接种方案并未加重病变。这些结果确凿地证明，给大鼠接种抗支原体呼吸道疾病疫苗是可行的，也表明全身接种疫苗可能比鼻内接种疫苗为肺部提供更大的保护，至少在使用等量抗原剂量时如此。
